O
GOSS icon

OrbiMed’s Gossamer Bio GOSS Stock Holding History

OrbiMed’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-683,000
Closed -$7.72M – 150
2021
Q4 		$7.72M Buy
+683,000
New +$8.11M 0.1% 123

Other funds holding GOSS

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed's GOSS Position: Q1 2022 in Review

OrbiMed sold out of Gossamer Bio (GOSS) in Q1 2022, closing a stake of 683,000 shares — an estimated $7.72M sold.

OrbiMed first reported a position in GOSS in Q4 2021 and held it in 1 quarter. The position peaked at $7.72M in Q4 2021. 141 funds tracked by Wall St. Rank hold GOSS as of Q1 2022.

  • OrbiMed reported no remaining Gossamer Bio position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 683,000 Gossamer Bio shares in Q1 2022, an estimated $7.72M.
  • OrbiMed first reported a position in Gossamer Bio in Q4 2021 and held it in 1 quarter.
  • OrbiMed's Gossamer Bio position peaked at $7.72M in Q4 2021.
  • 141 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.